Cibc World Markets Corp Acquires 13,255 Shares of Catalent, Inc. (NYSE:CTLT)

Cibc World Markets Corp raised its holdings in shares of Catalent, Inc. (NYSE:CTLTFree Report) by 133.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,205 shares of the company’s stock after acquiring an additional 13,255 shares during the quarter. Cibc World Markets Corp’s holdings in Catalent were worth $1,043,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. BNP Paribas Asset Management Holding S.A. raised its holdings in Catalent by 1.9% during the 4th quarter. BNP Paribas Asset Management Holding S.A. now owns 17,850 shares of the company’s stock valued at $802,000 after acquiring an additional 328 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its holdings in Catalent by 6.2% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,703 shares of the company’s stock valued at $256,000 after acquiring an additional 331 shares during the period. Arizona State Retirement System raised its holdings in Catalent by 0.7% during the 4th quarter. Arizona State Retirement System now owns 49,546 shares of the company’s stock valued at $2,226,000 after acquiring an additional 365 shares during the period. Treasurer of the State of North Carolina raised its holdings in Catalent by 0.5% during the 3rd quarter. Treasurer of the State of North Carolina now owns 81,729 shares of the company’s stock valued at $3,721,000 after acquiring an additional 421 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in Catalent by 2.3% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 18,907 shares of the company’s stock valued at $849,000 after acquiring an additional 434 shares during the period.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Stephens restated an “equal weight” rating and set a $63.50 price target on shares of Catalent in a research report on Thursday, April 4th. Royal Bank of Canada restated a “sector perform” rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, February 20th. Finally, StockNews.com assumed coverage on shares of Catalent in a research report on Thursday, June 6th. They set a “sell” rating for the company. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $53.14.

Get Our Latest Research Report on Catalent

Catalent Stock Down 0.4 %

Shares of NYSE:CTLT opened at $56.19 on Tuesday. The firm has a fifty day moving average of $55.73 and a 200 day moving average of $52.28. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51. Catalent, Inc. has a 52-week low of $31.80 and a 52-week high of $60.20. The firm has a market capitalization of $10.17 billion, a PE ratio of -9.21, a price-to-earnings-growth ratio of 6.69 and a beta of 1.20.

Catalent (NYSE:CTLTGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.36). Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. The business had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.11 billion. As a group, research analysts anticipate that Catalent, Inc. will post 0.28 EPS for the current fiscal year.

Insider Buying and Selling at Catalent

In other Catalent news, insider Ricky Hopson sold 1,401 shares of the company’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the sale, the insider now directly owns 20,617 shares in the company, valued at $1,118,678.42. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.31% of the company’s stock.

About Catalent

(Free Report)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

Featured Stories

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLTFree Report).

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.